MSD’s verubecestat fails again in Alzheimer’s trial
The Alzheimer’s disease research field has taken yet another hit with the failure of MSD’s verubecestat in a late-stage trial.
Read More
Tag: APECS
Merck pulls plug on late-stage Alzheimer’s trial
Merck & Co has terminated a Phase II/III trial testing its investigational medicine verubecestat in patients with mild to moderate Alzheimer’s disease.
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
